AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression
Status: | Recruiting |
---|---|
Conditions: | Depression, Depression, Major Depression Disorder (MDD) |
Therapuetic Areas: | Psychiatry / Psychology, Pulmonary / Respiratory Diseases |
Healthy: | No |
Age Range: | 18 - 65 |
Updated: | 2/28/2019 |
Start Date: | March 5, 2018 |
End Date: | June 30, 2019 |
Contact: | Ashley Sullivan |
Email: | VSGCL003@cato.com |
Phone: | 919-443-3403 |
Double-Blind, Placebo-Controlled, Phase 2 Trial to Test Efficacy and Safety of AV-101 (L-4-chlorokynurenine) as Adjunct to Current Antidepressant Therapy in Patients With Major Depressive Disorder (the ELEVATE Study)
The study will evaluate the safety and efficacy of AV-101.
Inclusion Criteria:
- Diagnosed with MDD, single or recurrent, and currently experiencing a MDE of at least
8 weeks in duration.
- Has a history of inadequate response to at least 1 approved antidepressant including
at least 1 and no more than 3 during the current depressive episode.
- Meet the threshold on the total HAMD-17 score of > 20
- If female, a status of nonchildbearing potential or use of an acceptable form of birth
control.
- Body mass index between 18 to 40 kg/m2.
- Other criteria may apply
Exclusion Criteria:
- History of bipolar disorder, schizophrenia or schizoaffective disorders, or any
history of psychotic symptoms in the current or previous depressive episodes.
- Any Axis I or Axis II Disorder, which at screening is clinically predominant to their
MDD or has been predominant to their MDD at any time within 6 months prior to
screening.
- Women who are pregnant or breastfeeding or a positive pregnancy test at screening or
baseline.
- Currently taking a prohibited adjunct therapy. Such drugs must be washed out for at
least 4 weeks prior to baseline.
- Current diagnosis of moderate or severe substance use (including alcohol) disorder
(abuse or dependence, as defined by DSM-5), with the exception of nicotine dependence,
at screening or within 6 months prior to screening.
- In the opinion of the investigator, the subject has a significant risk for suicidal
behavior
- Has received electroconvulsive therapy, or had repetitive transcranial magnetic
stimulation in the current episode.
- Has received vagus nerve stimulation at any time prior to screening.
- Any current or past history of any physical condition, which in the investigator's
opinion might put the subject at risk or interfere with study results interpretation.
We found this trial at
21
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials